An overview of T2D long-term complications and treatment options
The FDA has approved Mallinckrodt's New Drug Application for Pennsaid (diclofenac sodium topical solution) 2% w/w for Pain of Osteoarthritis....
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.
Overview of the role of type 2 inflammation in eosinophilic esophagitis (EoE), EoE burden, and the pathophysiology of multiple inflammatory diseases.
TheracosBio announced that the FDA has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
The FDA has announced that its review of investigational Type 2 Diabetes therapy Nesina (alogliptin), from Takeda, along with the...
An interim analysis of a pivotal Phase III study BOLERO 2, showed Afinitor (everolimus) tablets from Novartis used in combination...
Novartis has announced results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN 457 (secukinumab) in...
Lexicon Pharmaceuticals announced topline data from the Phase III SOTA-EMPA study for Zynquista (sotagliflozin) in type 2 diabetes. The topline...